We are creating some awesome events for you. Kindly bear with us.

HKSTP biotech firms to accelerate cancer treatment development

Image Credits: HKSTP, Press Release

Two biomedical technology companies based at the Hong Kong Science Park have signed a memorandum of understanding to form a strategic collaboration to accelerate cancer treatment development. The two will work together to improve treatment options for patients with gastrointestinal (GI) cancers.

The partnership will see the two Hong Kong companies join forces to develop companion diagnostic tests to readily identify CDH17-positive patients for ARB202 treatment. The goal is to deliver tests that will be available for clinical studies and commercial use, and ultimately covered by regulatory approvals in Hong Kong and the Mainland, to offer a new treatment option for GI cancers.

One firm, Sanomics, develops and deploys innovative genetic and genomic technologies. It aims to provide safe and reliable liquid/ tissue-based genomic diagnostic tests for personalised cancer treatment solutions for patients across Asia. The company has extensive expertise and capability in researching, developing, manufacturing, and marketing companion diagnostics. Companion diagnostics are tests co-developed with drugs to aid in selecting or excluding patient groups for treatment for that drug, based on their biological characteristics to determine their responsiveness to therapy.

The second firm, Arbele, is a biotech and biopharmaceutical company focused on inventing proprietary immunotherapeutic platforms to accelerate the development of antibody-based biologics to treat GI cancers and solid tumours. Arbele’s lead antibody, ARB202, binds to the CDH17 gene and the T-cell receptor antigen CD3, to effect cancer immunotherapy at tumour sites.

Through Good Manufacturing Practice (GMP) manufacturing and Good Laboratory Practice (GLP) pre-clinical safety trials, ARB202 is an investigational new drug (IND) ready asset, promising to be a “first-in-class” innovative medicine for clinical trials to treat GI cancer patients in Hong Kong, China, and beyond.

The Head of the Biomedical Technology Cluster at Hong Kong Science and Technology Parks Corporation (HKSTP), said that the two local pioneers joining forces to create a new paradigm in cancer treatment are encouraging. HKSTP aims to accelerate the translation of promising biomedical research into revolutionary treatment that makes a real impact on healthcare, he said.

The partnership is a great example to demonstrate the synergy created within the Park’s ecosystem. Moreover, the Park will be launching a new open innovation platform MedICon to facilitate even more collaborations.

The CEO at Sanomics stated that in collaborating with Arbele, they will be putting their expertise and resources together, to advance a new drug which can provide healthcare professionals with new treatment options, and hope to millions of people around the world.

The Founder and President at Arbele noted that using the expertise and resources from Sanomics, this partnership established on the Science Park campus will certainly advance the company’s CDH17 companion diagnostics regulatory approval and commercialisation from Hong Kong to Greater China markets.

HKSTP is host to a dynamic innovation and technology ecosystem with a thriving cluster of biomedical technology companies. It offers world-class shared facilities across the city as well as initiatives to support the R&D of biotech startups and companies. Biomedical technology is one of the strategic focuses of HKSTP. There are approximately 150 biotech companies at the Park, which have grown significantly over the past few years.

Sanomics is a member of HKSTP’s ELITE programme, an initiative which offers to fund high-potential tech companies with strong R&D capabilities from local and around the world, to set up operations at Hong Kong Science Park.

Meanwhile, Arbele is a graduate from HKSTP’s Incu-Bio, a four-year incubation programme which provides comprehensive support, from connecting stakeholders in investment and regulatory processes to developing a business plan as well as financial support and equipment to help biomedical startups develop and commercialise their innovations.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


CTC Global Singapore, a premier end-to-end IT solutions provider, is a fully owned subsidiary of ITOCHU Techno-Solutions Corporation (CTC) and ITOCHU Corporation.

Since 1972, CTC has established itself as one of the country’s top IT solutions providers. With 50 years of experience, headed by an experienced management team and staffed by over 200 qualified IT professionals, we support organizations with integrated IT solutions expertise in Autonomous IT, Cyber Security, Digital Transformation, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Well-known for our strengths in system integration and consultation, CTC Global proves to be the preferred IT outsourcing destination for organizations all over Singapore today.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com.


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and business services provider. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity and service.

Send this to a friend